Share this article on:

Our Vision for the Future of Inflammatory Bowel Diseases: Research, Innovations, and Controversies

Lashner, Bret MD, MPH; Cominelli, Fabio MD, PhD

Inflammatory Bowel Diseases: January 2017 - Volume 23 - Issue 1 - p 1
doi: 10.1097/MIB.0000000000001018

Received December 05, 2016

Accepted December 05, 2016

It is with excitement and humility that we have the honor to serve as Co-Editors-in-Chief of Inflammatory Bowel Diseases. For the past 22 years, Drs. Richard MacDermott and Robert Burakoff have stewarded the journal from its inception to its place as a premier scientific journal in the field. Their tireless efforts and innovations have made the journal what it is today. We plan to build on this solid foundation to make Inflammatory Bowel Diseases the home for the most important research advances, interesting innovations in patient treatment, and resolution of timely controversies in our field.

Our overall goal is to make the journal interesting and relevant to our readers. By reading Inflammatory Bowel Diseases on a monthly basis, you should be able to better understand the pathogenesis and epidemiology of inflammatory bowel disease (IBD), as well as innovative treatment advances. In addition, we will learn about the latest scientific discoveries in basic and translational research in intestinal inflammation and IBD. Ultimately, we should be able to deliver higher quality of care for our patients with IBD. To achieve these lofty goals, we have assembled a group of associate editors who are true experts in many different fields of IBD research. They are from North America and Europe and are very accomplished both academically and scientifically. As a group, they will be able to influence the journal's scope and direction through weekly conference calls and solicitation of reviews and original research. Our outstanding Editorial Board will be providing behind-the-scenes advice and prompt peer reviews when needed. To our many, many reviewers, we need to thank you in advance for your insights and expertise. For authors, we promise fair and comprehensive review of your submission, a quick turnaround time, and e-publishing ahead of print. The success of Inflammatory Bowel Diseases depends on all of you. Thank you for your help.

Our Managing Editor, Meghann Knowles from J&J Editorial, has already provided valuable support. We have also been working closely with Stella Bebos and Jennifer Sollenberger from Wolters Kluwer Publishing. All the editors look forward to working with them in the coming years.

Finally, we need to thank the Crohn's and Colitis Foundation of America for giving all of us this opportunity. Their support of IBD research and education is exemplary. We will be featuring, as much as possible, Crohn's and Colitis Foundation of America–funded research in the journal. Marjorie Merrick, the Crohn's and Colitis Foundation of America Vice President of Research Special Projects has been guiding the journal for the past 22 years and will be closely working with us going forward. Thank you Crohn's and Colitis Foundation of America and thank you Marjorie.

Please turn the page and enjoy the January, 2017 issue of Inflammatory Bowel Diseases.

Bret Lashner, MD, MPH

Bret Lashner, MD, MPH

Fabio Cominelli, MD, PhD

Fabio Cominelli, MD, PhD

© Crohn's & Colitis Foundation of America, Inc.